Caitlin Flanagan


Adhering to Oral Therapy for HER2+ Metastatic Breast Cancer

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.

Progression of HER2+ Metastatic Breast Cancer

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.